Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791464 | 1.00 | CTSK (0.51) | CTSKCTSSTDP1ATMCYP1A2 | |
| SCHEMBL6791457 | 1.00 | CTSK (0.51) | CTSKCTSSTDP1ATMCYP1A2 | |
| SCHEMBL19695766 | 1.00 | CTSK (0.51) | CTSKCTSSTDP1ATMCYP1A2 | |
| SCHEMBL14682825 | 0.97 | CTSK (0.49) | CTSKCTSSTDP1ATMCYP1A2 | |
| SCHEMBL29727325 | 0.92 | CTSK (0.50) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30788958 | 0.92 | CTSK (0.46) | CTSKCTSSTDP1ATMCYP1A2 | |
| SCHEMBL17449762 | 0.89 | CTSK (0.48) | CTSKCTSSTDP1ATMCYP1A2 | |
| SCHEMBL4981797 | 0.87 | CTSK (0.52) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL19695765 | 0.87 | CTSK (0.51) | CTSKCTSSTDP1ATMCYP1A2 | |
| SCHEMBL613038 | 0.87 | CTSK (0.51) | CTSKCTSSTDP1ATMCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| CN-114929705-B | MLL1 inhibitors and anticancer agents | 诺华公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4013754-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-07-24 | — | — | EP | disclosed |
| CN-114929705-A | MLL1 inhibitor and anticancer agent | 诺华公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-4013754-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-9840457-B2 | Lysine isotopologues, compositions comprising the same and methods of synthesis | CAMBRIDGE ISOTOPE LABORATORIES, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840457-B2 | Lysine isotopologues, compositions comprising the same and methods of synthesis | CAMBRIDGE ISOTOPE LABORATORIES, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160016890-A1 | LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS | CAMBRIDGE ISOTOPE LABORATORIES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160016890-A1 | LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS | CAMBRIDGE ISOTOPE LABORATORIES, INC. | 2016-01-21 | — | — | US | disclosed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-6410580-B1 | ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | MLLT1, BMI1, DOT1L | CTSK 4303/4885CTSS 4653/4885TDP1 1975/4885 |
| US-20160016890-A1 | LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS | PLOD1, PHYKPL, AADAT | CTSK 785/4885CTSS 2046/4885TDP1 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.